Drug intelligence / Profile preview

Zindac

Development stage: Unknown
Lead developer: Martin & Brown Biosciences
Modality: Small Molecules
Administration: Oral

Overview

Zindac is an oral generic formulation of ranitidine, a histamine H2 receptor antagonist, manufactured by Martin & Brown Biosciences. It is primarily used to reduce gastric acid production in the treatment and prevention of conditions such as peptic ulcer disease, gastroesophageal reflux disease (GERD), heartburn, and indigestion. By competitively blocking histamine H2 receptors on the parietal cells of the stomach, it effectively inhibits both basal and stimulated gastric acid secretion. It is also utilized to prevent gastric injury associated with non-steroidal anti-inflammatory drugs (NSAIDs) and stress-related mucosal damage in critically ill patients.

Brand names: Zindac

Targets

HRH2 (Histamine H2 Receptor)

Beyond the preview

Go deeper on Zindac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zindac.

Explore the full profile